Singapore, Sept. 1 -- Osivax, a France based clinical-stage biopharmaceutical company developing differentiated influenza vaccines designed to generate broad-spectrum immune responses, and GC Biopharma, a leading South Korean biopharmaceutical company with extensive experience in vaccines and plasma-derived products, have announced a long-term collaboration to develop and commercialise a next-generation seasonal influenza vaccine candidate designed to provide broader and more durable protection against a wide range of influenza strains.

Under the agreement, the companies will develop the combination of OVX836, Osivax's broad-spectrum influenza A vaccine candidate targeting the highly conserved nucleoprotein (NP), with GC FLU, GC Biopharm...